MaxCyte to join Russell 2000 and 3000 Index
- BySeeking Alpha-
MaxCyte (MXCT) to join the Russell 3000 and Russell 2000 indices, effective after the U.S
MaxCyte (MXCT) to join the Russell 3000 and Russell 2000 indices, effective after the U.S
MaxCyte (MXCT): Q2 GAAP EPS of -$0.05 beats by $0.01.Revenue of $7.1M (+37.9% Y/Y) beats by $1.31M.Press Release
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more...
With shares in MaxCyte Inc (LON:MXCT) currently trading close to a 52 week high, a question many on the sidelines probably have is: "was I too late to buy them"?The share price is...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Sell | Strong Buy |
| Technical Indicators | Strong Sell | Sell | Sell | Sell | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 4,829.50 | 4,950.00 | 4,791.00 | -180.5 | -3.60% | 9.38M | London | |||
| 213.00 | 215.80 | 211.50 | +1.00 | +0.47% | 26.16M | London | |||
| 458.50 | 467.50 | 454.00 | -1.00 | -0.22% | 388.39K | London | |||
| 420.00 | 420.00 | 415.00 | -12.00 | -2.78% | 586.09K | London | |||
| 3.40 | 3.90 | 3.20 | +0.32 | +10.21% | 61.36M | London | |||
| 21.00 | 22.00 | 21.00 | -0.75 | -3.41% | 1.03M | London | |||
| 75.00 | 76.20 | 71.00 | -2.00 | -2.60% | 827.88K | London | |||
| 717.00 | 743.60 | 710.20 | -1.80 | -0.25% | 1.43M | London | |||
| 532.00 | 560.00 | 532.00 | -25.00 | -4.49% | 100.28K | London | |||
| 6.20 | 6.20 | 6.20 | +0.35 | +5.98% | 1.18M | London | |||
| 1,385.00 | 1,415.00 | 1,370.00 | +5.00 | +0.36% | 9.52K | London | |||
| 279.20 | 286.60 | 278.50 | -3.50 | -1.24% | 2.27M | London | |||
| 128.00 | 128.00 | 128.00 | +3.50 | +2.81% | 89.80K | London | |||
| 1,935.00 | 1,940.00 | 1,919.00 | 0.00 | 0.00% | 0.00 | London | |||
| 66.50 | 66.50 | 66.50 | 0.00 | 0.00% | 18.03K | London |
MaxCyte, Inc. (MaxCyte) is a life sciences company. The Company is focused on advancing the discovery, development and commercialization of cell therapies. The Company provide cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. MaxCyte has developed and commercialized Flow Electroporation platform, which facilitates engineering of a wide variety of cells. The Company's ExPERT platform, which is based on Flow Electroporation technology, is designed to address the expanding cell therapy market, and used across the continuum of the cell therapy sector. The ExPERT family of products includes: three instruments, the ATx, STx and GTx. MaxCyte has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.